{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T21:08:00Z","timestamp":1788469680490,"version":"build-2803163510"},"reference-count":36,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:00:00Z","timestamp":1722297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Bayer Netherlands B.V.","award":["PO2150850929"],"award-info":[{"award-number":["PO2150850929"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMAHP"],"abstract":"<jats:p>With the increasing pipeline of cell and gene therapies (CGTs) and the expected surge in the number of approvals, understanding the market access landscape becomes crucial for timely patient access. This study evaluates the challenges Dutch stakeholders encounter in CGT market access, offering insights for improving time-to-patient access. A traditional literature review was conducted to identify market access challenges and solutions for CGTs. Based on the findings, participants for semi-structured interviews, designed using an interview guide adapted to the Dutch context, were selected to capture diverse perspectives on market access. This review included 124 relevant articles out of 2449, covering several aspects of market access of CGTs. Subsequently, interviews with 16 stakeholders from academia, patient advocacy groups, manufacturers, health insurers, payers, hospital pharmacists, healthcare practitioners, and the Association of Innovative Medicines were conducted. Stakeholders identified challenges and proposed solutions for reimbursement package management, clinical trials, health economics, payment models, and procedural and organisational aspects. Thematic analysis revealed unique country-specific challenges and solutions in the Netherlands. This research provides insights into these challenges and potential solutions, emphasising the need for collaborative efforts among stakeholders to develop practical and multidisciplinary measures to improve the market access landscape for CGTs in the country.<\/jats:p>","DOI":"10.3390\/jmahp12030015","type":"journal-article","created":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T18:04:59Z","timestamp":1722535499000},"page":"181-198","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Market Access Challenges and Solutions in Cell and Gene Therapy in The Netherlands"],"prefix":"10.3390","volume":"12","author":[{"given":"Rimma","family":"Velikanova","sequence":"first","affiliation":[{"name":"Department of Health Sciences, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands"},{"name":"Asc Academics, Hereweg 120, 9725 AK Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Wolters","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands"},{"name":"Asc Academics, Hereweg 120, 9725 AK Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hinko S.","family":"Hofstra","sequence":"additional","affiliation":[{"name":"Asc Academics, Hereweg 120, 9725 AK Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten J.","family":"Postma","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands"},{"name":"Department of Economics, Econometrics and Finance, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands"},{"name":"Health-Ecore, Utrechtseweg 60, 3704 HE Zeist, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelis","family":"Boersma","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands"},{"name":"Health-Ecore, Utrechtseweg 60, 3704 HE Zeist, The Netherlands"},{"name":"Department of Management Sciences, Open University, Valkenburgerweg 177, 6419 AT Heerlen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,30]]},"reference":[{"key":"ref_1","unstructured":"(2023, December 03). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/."},{"key":"ref_2","unstructured":"Simon Alfano, A.G., Alberto, L., and Pablo, S. (2024, January 20). Eight Imperatives for Launching Cell and Gene Therapies. Available online: https:\/\/www.mckinsey.com\/industries\/life-sciences\/our-insights\/eight-imperatives-for-launching-cell-and-gene-therapies."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1822666","DOI":"10.1080\/20016689.2020.1822666","article-title":"Health economic evaluation of gene replacement therapies: Methodological issues and recommendations","volume":"8","author":"Thokagevistk","year":"2020","journal-title":"J. Mark. Access Health Policy"},{"key":"ref_4","unstructured":"Marsden, G., and Towse, A. (2023, December 01). Exploring the Assessment and Appraisal of Regenerative Medicines and Cell Therapy Products: Is the NICE Approach Fit for Purpose. Available online: https:\/\/www.ohe.org\/publications\/exploring-assessment-and-appraisal-regenerative-medicines-and-cell-therapy-products\/."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2002006","DOI":"10.1080\/20016689.2021.2002006","article-title":"An overview of health technology assessments of gene therapies with the focus on cost-effectiveness models","volume":"9","author":"Paterak","year":"2021","journal-title":"J. Mark. Access Health Policy"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1080\/14737167.2021.1969229","article-title":"Considering potential solutions for limitations and challenges in the health economic evaluation of gene therapies","volume":"21","author":"Qiu","year":"2021","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta21070","article-title":"The assessment and appraisal of regenerative medicines and cell therapy products: An exploration of methods for review, economic evaluation and appraisal","volume":"21","author":"Hettle","year":"2017","journal-title":"Health Technol. Assess."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2217\/cer-2017-0068","article-title":"Gene therapy: Evidence, value and affordability in the US health care system","volume":"7","author":"Hampson","year":"2018","journal-title":"J. Comp. Eff. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s10198-018-1007-x","article-title":"Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare","volume":"20","author":"Hampson","year":"2019","journal-title":"Eur. J. Health Econ."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.jval.2019.03.012","article-title":"Analytic considerations in applying a general economic evaluation reference case to gene therapy","volume":"22","author":"Drummond","year":"2019","journal-title":"Value Health"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s40273-020-00956-w","article-title":"Recalibrating health technology assessment methods for cell and gene therapies","volume":"38","author":"Angelis","year":"2020","journal-title":"Pharmacoeconomics"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s10198-020-01212-w","article-title":"HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies","volume":"21","author":"Coyle","year":"2020","journal-title":"Eur. J. Health Econ."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.jval.2020.04.1833","article-title":"A review of methodological considerations for economic evaluations of gene therapies and their application in literature","volume":"23","author":"Klungel","year":"2020","journal-title":"Value Health"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Simoens, S., De Groote, K., and Boersma, C. (2022). Critical reflections on reimbursement and access of advanced therapies. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.771966"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s40273-015-0307-6","article-title":"Reimbursement decisions for pharmaceuticals in Sweden: The impact of disease severity and cost effectiveness","volume":"33","author":"Svensson","year":"2015","journal-title":"Pharmacoeconomics"},{"key":"ref_16","unstructured":"(2024, January 23). Principles for Priority Setting in Health Care. Available online: https:\/\/www.regjeringen.no\/contentassets\/439a420e01914a18b21f351143ccc6af\/en-gb\/pdfs\/stm201520160034000engpdfs.pdf."},{"key":"ref_17","unstructured":"(2024, January 23). Changes We\u2019re Making to Health Technology Evaluation. Available online: https:\/\/www.nice.org.uk\/Media?Default\/About\/what-we-do\/our-programmes\/technology-appraisals\/methods-processes-and-topic-selection-review-board-paper-appendix.docx."},{"key":"ref_18","unstructured":"(2024, January 27). Adapted Value Assessment Methods for High-Impact \u201cSingle and Short-Term Therapies\u201d (SSTs). Available online: https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/ICER_SST_FinalAdaptations_111219.pdf."},{"key":"ref_19","unstructured":"(2023, June 11). Vergoeding Intramurale Geneesmiddelen: De Add-on Prestatie. Available online: http:\/\/www.hollandbio.nl\/wp-content\/uploads\/2020\/12\/infographic-vergoeding-intramurale-geneesmiddelen_final.pdf."},{"key":"ref_20","unstructured":"(2024, June 10). Vergoeding Intramurale Geneesmiddelen: Van EMA Registratie Tot Add-on. Available online: https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2023\/02\/infographic-vergoeding-intramurale-geneesmiddelen_versie-jan-2023.pdf."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13023-022-02260-6","article-title":"An international comparative analysis of public reimbursement of orphan drugs in Canadian provinces compared to European countries","volume":"17","author":"Ward","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_22","unstructured":"Kuipers, E. (2023, July 20). Wijziging Beleidsregels voor de Toepassing van de Sluis voor dure Geneesmiddelen op Grond van Artikel 2.4a van het Besluit Zorgverzekering. Available online: https:\/\/open.overheid.nl\/documenten\/ronl-a04e9c698c6915588ffed5b381e5f2b7097c4bc6\/pdf."},{"key":"ref_23","unstructured":"(2023, July 26). Sluis Voor Dure Geneesmiddelen. Available online: https:\/\/www.zorginstituutnederland.nl\/over-ons\/programmas-en-samenwerkingsverbanden\/horizonscan-geneesmiddelen\/sluis-voor-dure-geneesmiddelen."},{"key":"ref_24","unstructured":"(2023, July 26). Pakketadvies Sluisgeneesmiddel Ciltacabtagene Autoleucel (Carvykti\u00ae) Voor de Behandeling van Multipel Myeloom. Available online: https:\/\/www.zorginstituutnederland.nl\/over-ons\/publicaties\/adviezen\/2022\/10\/20\/pakketadvies-sluisgeneesmiddel-ciltacabtagene-autoleucel-carvykti."},{"key":"ref_25","unstructured":"(2023, July 26). Bluebird Bio Reports Second Quarter Financial Results and Provides Operational Update. Available online: https:\/\/investor.bluebirdbio.com\/news-releases\/news-release-details\/bluebird-bio-reports-second-quarter-financial-results-and."},{"key":"ref_26","unstructured":"(2024, May 26). Pakketadvies Sluisgeneesmiddel Atidarsagene Autotemcel (Libmeldy\u00ae) Voor de Behandeling van Metachromatische Leukodystrofie (MLD). Available online: https:\/\/www.zorginstituutnederland.nl\/over-ons\/publicaties\/adviezen\/2022\/09\/27\/pakketadvies-sluisgeneesmiddel-atidarsagene-autotemcel-libmeldy."},{"key":"ref_27","unstructured":"Lau, F., and Kuziemsky, C. (2017). Methods for literature reviews. Handbook of ehealth Evaluation: An Evidence-Based Approach, University of Victoria."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1080\/0142159X.2020.1755030","article-title":"Thematic analysis of qualitative data: AMEE Guide No. 131","volume":"42","author":"Kiger","year":"2020","journal-title":"Med. Teach."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"675","DOI":"10.3233\/JND-221540","article-title":"Gene therapy for neuromuscular diseases: Health economic challenges and future perspectives","volume":"9","author":"Landfeldt","year":"2022","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Qiu, T., Pochopien, M., Liang, S., Saal, G., Paterak, E., Janik, J., and Toumi, M. (2022). Gene therapy evidence generation and economic analysis: Pragmatic considerations to facilitate fit-for-purpose health technology assessment. Front. Public Health, 10.","DOI":"10.3389\/fpubh.2022.773629"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.jval.2021.05.008","article-title":"Hemophilia gene therapy value assessment: Methodological challenges and recommendations","volume":"24","author":"Garrison","year":"2021","journal-title":"Value Health"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/hae.14413","article-title":"Health technology assessment for gene therapies in haemophilia","volume":"28","author":"Neumann","year":"2022","journal-title":"Haemophilia"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jval.2022.07.004","article-title":"Challenges for economic evaluations of advanced therapy medicinal products: A systematic review","volume":"26","author":"Epstein","year":"2023","journal-title":"Value Health"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s40290-022-00443-x","article-title":"Pricing and market access challenges in the era of one-time administration cell and gene therapies","volume":"36","author":"Sabatini","year":"2022","journal-title":"Pharm. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"S297","DOI":"10.1016\/j.jval.2022.04.062","article-title":"P48 Are Health Technology Assessment (HTA) Bodies Responding to the Assessment Challenges Posed By Cell and Gene Therapies?","volume":"25","author":"Fornaro","year":"2022","journal-title":"Value Health"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/14737167.2023.2197214","article-title":"Recommendations for economic evaluations of cell and gene therapies: A systematic literature review with critical appraisal","volume":"23","author":"Toumi","year":"2023","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."}],"container-title":["Journal of Market Access &amp; Health Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2001-6689\/12\/3\/15\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:26:22Z","timestamp":1760109982000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2001-6689\/12\/3\/15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,30]]},"references-count":36,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["jmahp12030015"],"URL":"https:\/\/doi.org\/10.3390\/jmahp12030015","relation":{},"ISSN":["2001-6689"],"issn-type":[{"value":"2001-6689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,30]]}}}